ep beat consensu iqv ep beat
better revenu off-set lower profit factor
line ad importantli unveil initi guidanc
consensu reflect acceler core rd revenue growth
cc continu strength ta cc ep
move stronger revenu profit run rate
tp move higher view
revenu ahead qtrli book impress btb revenu rose
cc well ahead plan cc strength ta
cc nice ahead estimate cc rd also well view
cc vs estimate cc post yet anoth except strong
quarterli net book-to-bil basi estimate
vs estimate ttm net new book end
backlog rise sequenti billion backlog burn
basi vs gross margin deterior bp
bp plan sg expens fell bp bp plan
ebitda margin expand bp albeit bp view
gener million cash help fund million share
repurchas billion cash reserv stand million
ltm net leverag stand
share grind higher share ytd vs
momentum continu latest ep upsid initi
robust guidanc well presum build traction
offer detail expect call initi guidanc
encouragingli street across metric reflect solid
cc revenu growth ep consensu
midpoint bia remain posit predic sustain
strength outsourc demand uniqu abil leverag global data
asset dilig cost structur manag risk new busi
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
iqvia inc world largest contract research organ
cro lead healthcar inform technolog servic
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario support bull
sotp scenario assum cost synergi im merger
exceed expect substanti cross sell cro
commerci servic exist new client greater new project
award due broader diversifi servic offer
pronounc strength spend fundament outsourc
grey sky scenario support bear
sotp scenario assum cost synergi take longer
expect captur integration-rel miscu includ
disrupt servic client capit deploy misstep
weaken demand outsourc relev
allow improv manag product portfolio regulatori life-cycle via
autom high-volum task cut cost improv data accuraci
januari also announc two new capabl enabl clinic team
share cross-trial train materi easili studi team abil
pass train materi safeti notif across studi geograph locat
site role therebi reduc site workload platform improv simplifi
work sponsor alik remov redund train receipt
enhanc transpar audit-trail document permit automat
identif noncompli site personnel
compani mention price
